Genmab A/S (GNMSF)
| Market Cap | 20.74B +16.9% |
| Revenue (ttm) | 4.13B +22.3% |
| Net Income | 788.00M -37.9% |
| EPS | 12.65 -36.8% |
| Shares Out | n/a |
| PE Ratio | 26.32 |
| Forward PE | 21.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 60 |
| Open | 353.00 |
| Previous Close | 346.76 |
| Day's Range | 353.00 - 353.00 |
| 52-Week Range | 232.34 - 353.00 |
| Beta | 0.70 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell n... [Read more]
Financial Performance
In 2025, Genmab's revenue was $3.72 billion, an increase of 19.19% compared to the previous year's $3.12 billion. Earnings were $963.00 million, a decrease of -15.00%.
Financial StatementsNews
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; September 24, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 13,794 restricted stock units and 13,331 warrants ...
Genmab Transcript: Bank of America Global Healthcare Conference
Three late-stage oncology assets are set for pivotal phase III readouts in Q4 2026, with broad development programs and potential first-in-class positioning. Commercial launches for Rina-S, petosemtamab, and EPKINLY are targeted for 2027, supported by robust infrastructure and a strong royalty base.
Genmab Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Multiple late-stage assets are advancing, with six new phase III trials and strong financial growth. Petosemtamab and EPKINLY are poised for major data readouts in Q4, potentially setting new standards in head and neck, colorectal, and B-cell cancers.
Genmab A/S (CPH:GEN) -- Oncology Innovation and Growth | Artisan International Small-Mid Fund ...
Genmab A/S (CPH:GEN) -- Oncology Innovation and Growth | Artisan International Small-Mid Fund Q3 2026
Genmab Transcript: Wells Fargo 21st Annual Healthcare Conference
Three major phase III readouts are expected next quarter, including pivotal data for epcoritamab in first-line DLBCL, petosemtamab in head and neck cancer, and Rina-S in PROC. Epcoritamab and petosemtamab are positioned for significant commercial opportunities, with Rina-S aiming for best-in-class efficacy and broad indication expansion.
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 28,011 shares as a consequence of the exercise of employee warrants. The incr...
Notice to Convene an Extraordinary General Meeting of Genmab A/S
Company Announcement Genmab A/S to hold an Extraordinary General Meeting on Wednesday, October 7, 2026 COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) convenes an Extraordinary Gene...
Genmab price target raised to DKK 2,500 from DKK 2,250 at Deutsche Bank
Deutsche Bank analyst Emmanuel Papadakis raised the firm’s price target on Genmab (GMAB) to DKK 2,500 from DKK 2,250 and keeps a Buy rating on the shares. Published first on…
Genmab to Participate in Upcoming Investor Conferences
Media Release COPENHAGEN, Denmark; August 25, 2026 Genmab A/S (Nasdaq: GMAB) announced today that members of its E xecutive Committee will participat e in fireside chats at the following investor con...
Genmab Slides: Investor presentation
Genmab has posted slides in relation to its latest quarterly earnings report, which was published on August 22, 2026.
Genmab price target raised to $35 from $33 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Genmab (GMAB) to $35 from $33 and keeps an Equal Weight rating on the shares.
Genmab price target raised to $42 from $40 at Guggenheim
Guggenheim analyst Michael Schmidt raised the firm’s price target on Genmab (GMAB) to $42 from $40 and keeps a Buy rating on the shares after the company reported “robust” Q2…
Genmab A/S Q2 Earnings Call Highlights
Genmab A/S NASDAQ: GMAB reported first-half 2026 revenue growth of 25% year over year and raised its full-year financial outlook, citing continued momentum from DARZALEX, EPKINLY and the broader portf...
Genmab Earnings Call Transcript: Q2 2026
Revenue grew 25% year-over-year, driven by strong sales of EPKINLY and DARZALEX, with adjusted operating profit up 18%. Multiple late-stage data readouts are expected in Q4 2026 and early 2027, supporting a raised full-year revenue outlook and continued investment in pipeline expansion.
Genmab Quarterly report: Q2 2026
Genmab has published its Q2 2026 quarterly earnings report on August 6, 2026.
Genmab Slides: Q2 2026
Genmab has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Genmab reports Q2 revenue $1.155B vs. $925M last year
Reports Q2 net profit $303M vs. $336M last year. “The second quarter of 2026 delivered clinical progress for our late-stage portfolio. Epcoritamab continued to demonstrate its potential as a core…
Genmab raises FY26 revenue view to $4.325B-$4.525B from $4.065B-$4.395B
Narrows FY26 adjusted operating profit view to $1.065B-$1.385B from $900M-$1.4B. “Genmab (GMAB) is updating its revenue, adjusted operating expenses and adjusted operating profit guidance for 2026. Th...
Genmab, AbbVie provide clarification on Phase 3 EPCORE(R) DLBCL-1 trial
Genmab A/S (GMAB) and AbbVie (ABBV) provided clarification on the primary endpoints from the Phase 3 EPCORE(R) DLBCL-1 study evaluating monotherapy epcoritamab (DuoBody(R)-CD3xCD20), a T-cell engaging...
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
COPENHAGEN, Denmark & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today provided clarification on the primary endpoints from the Phase 3 EPCORE® DLBCL-1 stu...
Genmab upgraded to Buy from Hold at TD Cowen
TD Cowen analyst Yaron Werber upgraded Genmab (GMAB) to Buy from Hold with a price target of $43, up from $32. The firm is confident that Epkinly, rinatabart sesutecan and…
Genmab reports Q2 net sales of Darzalex $4.207B
Genmab (GMAB) announced that worldwide net trade sales of DARZALEX, or daratumumab, including sales of the subcutaneous, or SC, product, daratumumab and hyaluronidase-fihj, sold under the tradename DA...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026
Company Announcement Net sales of DARZALEX ® in the second quarter of 2026 totaled USD 4,207 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen ...
Genmab says EC grants marketing authorization for Tepkinly combo
Genmab (GMAB) announced that the European Commission granted marketing authorization for TEPKINLY in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or re...
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenali...